Medlive is pleased to share that all four of our submitted abstracts were accepted for presentation during the 67th ASH Annual Meeting and Exposition taking place December 6 to 9, 2025. Three will appear as e-publications and one will be presented as a poster during the meeting.
Poster Title: Accelerating Practical Solutions for Bispecific Antibody Consideration for Multiple Myeloma in the Community Setting: Findings from an Implementation Science Initiative
Publication Number: 2642
Session Date and Time: December 6, 2025, 5:30 PM to 7:30 PM
Supporter: Johnson & Johnson and Pfizer
Partner: Blood Cancer United
Advancing Community-Based Care Through Collaborative Initiatives
Our poster presentation highlights outcomes from Phase 1 of the Multiple Myeloma Quality Improvement Initiative with Premier. This four-phase effort focuses on practical approaches that help community-based clinicians integrate new therapeutic options with confidence.
The importance of this work is reflected in the perspective of our partner, Blood Cancer United (Formerly The Leukemia & Lymphoma Society), below:
“At Blood Cancer United, our mission is to ensure that every person facing a blood cancer diagnosis has access to the treatments, support and education that give them more life and more hope. Partnering with Medlive on this initiative — focused on accelerating practical solutions for bispecific antibody use in multiple myeloma within community settings — aligns directly with that goal. Together we’re driving evidence into practice, helping clinicians navigate new therapeutic pathways and extending the impact of innovation from academic centers into everyday care.”
– Karen DeMairo, MHSA, Vice President, Education, Support & Integration, Blood Cancer United
E-Abstract Publications
Three additional abstracts were accepted for e-publication. Each will appear in the ASH supplement of the Blood Journal.
Poster Title: National practice patterns and preferences in the use of fixed-duration versus treat-to-progression therapies for CLL
Publication Number: 8095
Supporter: AstraZeneca
Poster Title: Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton’s tyrosine kinase inhibitors
Publication Number: 8106
Supporter: AstraZeneca
Poster Title: Integrating bispecific antibodies into community myeloma care: Challenges, insights, and educational impact
Publication Number: 8134
Supporter: Johnson & Johnson
To learn more about partnering with Medlive to develop impactful CME programs in oncology and other therapeutic areas, visit our Contact Us page to connect with our team.
